Table 1 Characteristics of the patients in the total population, patients without medication at the time of BC diagnosis, and patients on at least one medication at the time of BC diagnosis
From: Concomitant medication, comorbidity and survival in patients with breast cancer
Category | Variable | Class | Total | No concomitant medication | At least one drug |
|---|---|---|---|---|---|
n (%) | 235 368 (100%) | 56 510 (24%) | 178 858 (76%) | ||
Pre-exposure covariates | |||||
Socio- demographic | Age at diagnosis (years) | 60.0 [50.0, 69.0] | 52.0 [45.0, 61.0] | 63.0 [53.0, 71.0] | |
Age at diagnosis (years, classes) | <30 | 1 124 (0.5) | 477 (0.8) | 647 (0.4) | |
30-39 | 10 539 (4.5) | 4 631 (8.2) | 5 908 (3.3) | ||
40-49 | 43 206 (18.4) | 17 582 (31.1) | 25 624 (14.3) | ||
50-59 | 58 003 (24.6) | 18 297 (32.4) | 39 706 (22.2) | ||
60-69 | 64 042 (27.2) | 10 994 (19.5) | 53 048 (29.7) | ||
70-79 | 39 163 (16.6) | 3 458 (6.1) | 35 705 (20.0) | ||
80+ | 19 291 (8.2) | 1 071 (1.9) | 18 220 (10.2) | ||
Deprivation index (quintiles) | 1st quintile (least deprived) | 46 323 (19.7) | 12 369 (21.9) | 33 954 (19.0) | |
2nd quintile | 46 688 (19.8) | 11 657 (20.6) | 35 031 (19.6) | ||
3rd quintile | 45 984 (19.5) | 11 021 (19.5) | 34 963 (19.5) | ||
4th quintile | 46 183 (19.6) | 10 504 (18.6) | 35 679 (19.9) | ||
5th quintile (most deprived) | 45 992 (19.5) | 9 538 (16.9) | 36 454 (20.4) | ||
Overseas départements | 4 198 (1.8) | 1 421 (2.5) | 2 777 (1.6) | ||
GP consultations* | 5.0 [3.0, 9.0] | 2.0 [1.0, 4.0] | 6.0 [4.0, 10.0] | ||
GP consultations* (classes) | 0 | 12 964 (5.5) | 8 421 (14.9) | 4 543 (2.5) | |
1–5 | 109 539 (46.5) | 38 489 (68.1) | 71 050 (39.7) | ||
6–11 | 32 701 (13.9) | 1 308 (2.3) | 31 393 (17.6) | ||
12+ | 80 164 (34.1) | 8 292 (14.7) | 71 872 (40.2) | ||
Gynecologist visits** | 0.0 [0.0, 1.0] | 1.0 [0.0, 1.0] | 0.0 [0.0, 1.0] | ||
Gynecologist visits** (classes) | 0 | 127 785 (54.3) | 28 225 (49.9) | 99 560 (55.7) | |
1 | 65 868 (28.0) | 17 694 (31.3) | 48 174 (26.9) | ||
2–3 | 35 290 (15.0) | 8 941 (15.8) | 26 349 (14.7) | ||
4+ | 6 425 (2.7) | 1 650 (2.9) | 4 775 (2.7) | ||
Mammographic screening before diagnosis | No | 146 945 (62.4) | 38 843 (68.7) | 108 102 (60.4) | |
Yes | 88 423 (37.6) | 17 667 (31.3) | 70 756 (39.6) | ||
Comorbid conditions | Comorbid conditions (binary) | No | 124 652 (53.0) | 44 872 (79.4) | 79 780 (44.6) |
Yes | 110 716 (47.0) | 11 638 (20.6) | 99 078 (55.4) | ||
Comorbid condition category | Cardiovascular | 60 146 (25.6) | 2 931 (5.2) | 57 215 (32.0) | |
Endocrine and metabolism | 51 588 (21.9) | 3 522 (6.2) | 48 066 (26.9) | ||
Psychiatric disorders | 30 372 (12.9) | 4 713 (8.3) | 25 659 (14.3) | ||
Frailty (proxy) | 11 888 (5.1) | 1 181 (2.1) | 10 707 (6.0) | ||
Pulmonary | 10 883 (4.6) | 750 (1.3) | 10 133 (5.7) | ||
Rheumatologic disease and connective tissue diseases | 7 918 (3.4) | 413 (0.7) | 7 505 (4.2) | ||
Gastrointestinal | 7 519 (3.2) | 752 (1.3) | 6 767 (3.8) | ||
Neurologic | 6 983 (3.0) | 746 (1.3) | 6 237 (3.5) | ||
Liver | 2 668 (1.1) | 324 (0.6) | 2 344 (1.3) | ||
Kidney | 2 524 (1.1) | 93 (0.2) | 2 431 (1.4) | ||
Other | 1 015 (0.4) | 103 (0.2) | 912 (0.5) | ||
Immune | 635 (0.3) | 84 (0.1) | 551 (0.3) | ||
Post-exposure covariates | |||||
BC biology | Inferred BC subtype | luminal | 153 109 (65.1) | 34 117 (60.4) | 118 992 (66.5) |
TNBC | 18 149 (7.7) | 5 532 (9.8) | 12 617 (7.1) | ||
HER2 + | 19 722 (8.4) | 5 974 (10.6) | 13 748 (7.7) | ||
Undefined | 44 388 (18.9) | 10 887 (19.3) | 33 501 (18.7) | ||
Nodal status | Node-negative | 191 164 (81.2) | 45 282 (80.1) | 145 882 (81.6) | |
Node-positive | 44 204 (18.8) | 11 228 (19.9) | 32 976 (18.4) | ||
BC treatment | Breast surgery | Partial mastectomy | 173 173 (73.6) | 40 238 (71.2) | 132 935 (74.3) |
Mastectomy | 62 195 (26.4) | 16 272 (28.8) | 45 923 (25.7) | ||
Radiotherapy | No | 34 683 (14.7) | 8 294 (14.7) | 26 389 (14.8) | |
Yes | 200 685 (85.3) | 48 216 (85.3) | 152 469 (85.2) | ||
Chemotherapy | No | 145 116 (61.7) | 29 421 (52.1) | 115 695 (64.7) | |
Yes | 90 252 (38.3) | 27 089 (47.9) | 63 163 (35.3) | ||
Endocrine therapy | No | 69 713 (29.6) | 18 628 (33.0) | 51 085 (28.6) | |
Yes | 165 655 (70.4) | 37 882 (67.0) | 127 773 (71.4) | ||
